BPC February 03 update

Esperion (ESPR) and The Medicines Company (MDCO) profit from Amgen data; Pulmatrix (PULM) to raise cash; Pernix (PTX) loses case with Glaxo

Price and Volume Movers

Esperion Therapeutics Inc (NASDAQ:ESPR) shares closed up 29% to $16.44 on the back of positive data released by Amgen (NASDAQ: AMGN) on Thursday from its FOURIER trial where the PCSK9 inhibitor, Repatha met both primary and secondary endpoints in reducing the risk of cardiovascular events. Esperion shares rose in anticipation that this would improve the chances of its hypercholesterolemia drug candidate, bempedoic acid, currently in Phase 3 development.

The Medicines Company (NASDAQ:MDCO), another company seen to benefit from yesterday’s data, saw its shares close up 21% to $45.96. The company is developing inclisiran in partnership with Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) for the treatment of hypercholesterolemia. Phase 3 development is expected to commence mid-year.

Pulmatrix, Inc., (NASDAQ: PULM) announced that it will to sell 950,000 shares at a price of $3.50 per share, in a registered direct offering for proceeds of $3.33m. Shares of the nano-cap company, which have soared over recent weeks, dropped sharply to close down 24% to $3.86.

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) shares fell 18% to $2.44 following its notice today that an arbitration tribunal have awarded damages and fees to the total of $35m to GlaxoSmithKline. The damages relate to the Treximet asset purchase agreement and supply agreement. 

Shares of Stemline Therapeutics Inc (NASDAQ:STML) recovered some of its losses from Thursday’s session when it closed down 43% following news that that a third patient had died during its Phase 2 trial of SL-401 for the treatment of Blastic plasmacytoid dendritic cell neoplasm (BPDCN). Shares of the company closed Friday up 17% to $6.55.

Axovant Sciences (NYSE: AXON) announced that it has entered into a $55m debt financing agreement with Hercules Capital, Inc. Shares closed 14% higher to $13.68.

Neos Therapeutics, Inc. (Nasdaq:NEOS) shares closed down 13% to $5.05. The company announced the pricing of its public offering of 5m shares at a price of $5 per share.

Other major price movers:


Cerulean Pharma Inc (NASDAQ:CERU): $1.30; +40%.

Actinium Pharmaceuticals Inc (NYSEMKT:ATNM): $1.36; +32%.

Alcobra Ltd (NASDAQ:ADHD): $1.36; +17%.

Orexigen Therapeutics, Inc. (NASDAQ:OREX): $4.10; +16%.

Ampliphi Biosciences Corp (NYSEMKT:APHB): $4.97; +16%.

Flex Pharma Inc (NASDAQ:FLKS): $4.46; +12%.



Benitec Biopharma (NASDAQ:BNTC): $2.67; -27%

Windtree Therapeutics Inc (NASDAQ:WINT): $1.43; -15%.

Histogenics Corp (NASDAQ:HSGX): $1.67; -12%.

Tenax Therapeutics Inc (NASDAQ:TENX): $0.709; -11%.

Aldeyra Therapeutics Inc (NASDAQ:ALDX): $5.00; -7%.

Pipeline update below:

Pipeline Database Updates

Drug Stage Catalyst

First and Second line locally advanced or metastatic urothelial cancer - bladder cancer

Approved Approved May 18, 2017.